Skip to main content
OpenTrials
Completed

NCT Number: NCT02866149

Analysis of Circulating Tumor Markers in the Blood (ALCINA)

Exploratory study on blood-borne biological markers and their correlation with clinical and pathological characteristics.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Neoplasm Metastasis Neoplasms Neoplastic Cells, Circulating Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Georges François Leclerc, Dijon, France

Loading trial locations.

About this study

Exploratory multi-cohort study including different types of cancer (different organs and/or different histological types).

Each kind of blood-borne biological markers analyses corresponds to a cohort.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with any tumoral disease (proven or suspected), of any type and stage
  • More than18 years old
  • Signed informed consent form

Additional inclusion criteria if a tumor sample is needed:

  • Tumor considered as accessible by biopsy
  • Normal blood coagulation tests on the last blood analysis

Non-inclusion Criteria:

  • Patient in detention or protected by the law
  • Patient who cannot comply with the study follow up for geographical, social or psychological reasons

Additional non-inclusion criteria if a tumor sample is needed:

  • Anticoagulant or antiaggregant that cannot be interrupted for the biopsy
  • central-nervous system metastases only (unless a diagnostic or curative surgery is planned before the inclusion in the study)

Treatment and study plan

Blood sampling

Biological

Up to 5 blood samplings can be performed at different time points

Tumor sampling

Procedure

One tumor sampling can be performed, if applicable

Stool sampling

Other

Up to 5 blood samplings can be performed at different time points

Primary outcomes

  1. Feasibility of the analysis of different blood-borne tumor biomarkers

    Time frame: 18 months

    Success rate of the tested detection techniques. The success rate of a given detection technique is calculated by the ratio " detection success " / " number of screened patients ".

Secondary outcomes

  1. Correlation with biological and clinical data

    Time frame: 18 months

    Number of biological analysis results correlated to clinical data. Establishment of a proof of concept

Sponsors and collaborators

Lead sponsor

Institut Curie

Other

Registry information

Official study title

Analysis of Circulating Tumor Markers in the Blood

Acronym: ALCINA

Important dates

Study start
2015
Primary completion
2024
Study completion
2024
First posted
Aug 15, 2016
Registry last updated
Oct 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.